Mithra and Searchlight Pharma announce filing of new drug submission for Estelle in Canada

Mithra

20 May 2020 - Searchlight Pharma's new drug submission for a novel combined oral contraceptive accepted for review by Health Canada.

Mithra and Searchlight Pharma announced today that Health Canada has accepted Searchlight Pharma's new drug submission for a novel combined oral contraceptive product.

Developed by Mithra, the product candidate is composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is produced by the human foetal liver during pregnancy.

Read Mithra press release

Michael Wonder

Posted by:

Michael Wonder